Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pharming Group (PHAR) stocks in Canada

Learn how to easily invest in Pharming Group stocks.

Pharming Group is a biotechnology business based in the US. Pharming Group stocks (PHAR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.04 – an increase of 5.09% over the previous week. Pharming Group employs 277 staff and has a trailing 12-month revenue of around $201.9 million.

How to buy stocks in Pharming Group

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PHAR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pharming Group stock price (NASDAQ:PHAR)

Use our graph to track the performance of PHAR stocks over time.

Pharming Group shares at a glance

Information last updated 2022-05-20.
Latest market close$8.26
52-week range$6.71 - $12.56
50-day moving average $8.47
200-day moving average $9.08
Wall St. target priceN/A
PE ratio 48.75
Dividend yield $0 (0%)
Earnings per share (TTM) $0.16

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Pharming Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Pharming Group price performance over time

Historical closes compared with the close of $8.26 from 2022-05-23

1 week (2022-05-17) 5.09%
1 month (2022-04-25) -3.15%
3 months (2022-02-25) -10.70%
6 months (2021-11-24) -3.62%
1 year (2021-05-21) N/A
2 years (2020-05-21) N/A
3 years (2019-05-21) N/A
5 years (2017-05-21) N/A

Is Pharming Group under- or over-valued?

Valuing Pharming Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pharming Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pharming Group's P/E ratio

Pharming Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, Pharming Group shares trade at around 49x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Pharming Group's EBITDA

Pharming Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.9 million.

The EBITDA is a measure of a Pharming Group's overall financial performance and is widely used to measure a its profitability.

Pharming Group financials

Revenue TTM $201.9 million
Operating margin TTM 10.17%
Gross profit TTM $177.7 million
Return on assets TTM 3.29%
Return on equity TTM 5.91%
Profit margin 5.42%
Book value $2.80
Market capitalisation $543.2 million

TTM: trailing 12 months

Pharming Group share dividends

We're not expecting Pharming Group to pay a dividend over the next 12 months.

Pharming Group share price volatility

Over the last 12 months, Pharming Group's shares have ranged in value from as little as $6.71 up to $12.56. A popular way to gauge a stock's volatility is its "beta".

PHAR.US volatility(beta: 1.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pharming Group's is 1.55. This would suggest that Pharming Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Pharming Group overview

Pharming Group N. V. , a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site